Profile data is unavailable for this security.
About the company
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
- Revenue in USD (TTM)161.32m
- Net income in USD-177.92m
- Incorporated2008
- Employees353.00
- LocationRegenxbio Inc9804 Medical Center DriveROCKVILLE 20850United StatesUSA
- Phone+1 (240) 552-8181
- Fax+1 (302) 655-5049
- Websitehttps://regenxbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immix Biopharma Inc | 0.00 | -23.56m | 382.28m | 18.00 | -- | 29.30 | -- | -- | -0.7742 | -0.7742 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -104.21 | -108.46 | -169.47 | -146.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.11 | -- | 176.33 | -- |
| Lineage Cell Therapeutics Inc | 10.82m | -67.66m | 382.34m | 70.00 | -- | 17.35 | -- | 35.35 | -0.2955 | -0.2955 | 0.0469 | 0.0957 | 0.1162 | -- | 40.66 | 154,514.30 | -72.50 | -20.81 | -81.52 | -24.54 | 97.84 | 90.99 | -624.16 | -331.61 | -- | -- | 0.004 | -- | 6.19 | 22.00 | 13.39 | -- | 5.13 | -- |
| Absci Corp | 2.82m | -114.60m | 383.45m | 156.00 | -- | 1.82 | -- | 136.22 | -0.903 | -0.903 | 0.022 | 1.40 | 0.0117 | -- | 2.25 | 18,044.87 | -47.73 | -37.10 | -54.08 | -41.33 | -- | -- | -4,071.19 | -1,697.47 | -- | -410.97 | 0.0065 | -- | -20.71 | 17.09 | 6.75 | -- | -18.12 | -- |
| Climb Bio Inc | 0.00 | -50.75m | 386.61m | 17.00 | -- | 2.18 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| Forte Biosciences Inc | 0.00 | -51.74m | 402.24m | 16.00 | -- | 4.78 | -- | -- | -4.49 | -4.49 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -89.96 | -64.69 | -110.72 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| Lenz Therapeutics Inc | 17.50m | -58.88m | 403.01m | 42.00 | -- | -- | -- | 23.03 | -2.11 | -2.11 | 0.6268 | -- | -- | -- | -- | 416,666.70 | -- | -39.77 | -- | -42.56 | -- | -- | -336.47 | -- | -- | -- | -- | -- | -- | -- | 60.07 | -- | -- | -- |
| Regenxbio Inc | 161.32m | -177.92m | 404.48m | 353.00 | -- | 2.51 | -- | 2.51 | -3.46 | -3.46 | 3.14 | 3.19 | 0.3089 | -- | 6.59 | 456,991.50 | -34.07 | -20.33 | -43.55 | -23.79 | 87.18 | 76.64 | -110.29 | -82.78 | -- | -6.74 | 0.5427 | -- | -7.66 | 18.79 | 13.81 | -- | -26.96 | -- |
| Allogene Therapeutics Inc | 0.00 | -212.02m | 404.51m | 226.00 | -- | 1.27 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
| Niagen Bioscience Inc | 124.71m | 20.43m | 410.20m | 104.00 | 21.15 | 5.79 | 19.35 | 3.29 | 0.243 | 0.243 | 1.48 | 0.8875 | 1.61 | 3.07 | 18.34 | 1,199,125.00 | 26.42 | -23.12 | 35.76 | -35.20 | 63.89 | 60.73 | 16.38 | -15.71 | 3.29 | -- | 0.00003 | -- | 19.18 | 16.56 | 273.15 | -- | -26.37 | -- |
| Kyverna Therapeutics Inc | 0.00 | -160.99m | 414.75m | 129.00 | -- | 2.09 | -- | -- | -3.72 | -3.72 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -61.17 | -- | -69.77 | -- | -- | -- | -- | -- | -- | -- | 0.0013 | -- | -- | -- | -111.17 | -- | -- | -- |
| Entrada Therapeutics Inc | 61.52m | -103.46m | 415.83m | 183.00 | -- | 1.22 | -- | 6.76 | -2.50 | -2.50 | 1.47 | 8.91 | 0.1272 | -- | 32.39 | 336,174.90 | -21.39 | -8.44 | -23.70 | -10.02 | -- | -- | -168.16 | -33.36 | -- | -- | 0.00 | -- | 63.38 | -- | 1,081.69 | -- | 38.04 | -- |
| Tectonic Therapeutic Inc | 0.00 | -67.30m | 417.00m | 51.00 | -- | 1.56 | -- | -- | -3.85 | -3.85 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -30.20 | -- | -32.12 | -- | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -35.40 | -- | -- | -- |
| Assembly Biosciences Inc | 37.19m | -38.55m | 421.68m | 73.00 | -- | 2.31 | -- | 11.34 | -4.81 | -4.81 | 4.33 | 11.55 | 0.2186 | -- | 81.56 | 509,465.80 | -22.66 | -41.01 | -31.44 | -47.70 | -- | -- | -103.65 | -319.31 | -- | -- | 0.00 | -- | 298.16 | 12.31 | 34.38 | -- | -55.21 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 30 Sep 2025 | 4.69m | 9.27% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 4.16m | 8.21% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.05m | 6.03% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2025 | 2.61m | 5.16% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 1.98m | 3.92% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2025 | 1.62m | 3.20% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 1.45m | 2.87% |
| AQR Capital Management LLCas of 30 Sep 2025 | 1.29m | 2.55% |
| Assenagon Asset Management SA (Germany)as of 31 Dec 2025 | 1.16m | 2.29% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.13m | 2.22% |
